Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 2

Please go HERE to read Part 1 of this article The company, GEMMABIO, will pursue a number of rare, large indications.  A new spinout, RareTx, will be dedicated to Orphan…

Continue Reading Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 2

Breakthrough FDA Approval Offers First-Ever Treatment for Life-Threatening Mitochondrial Energy Disorder

The U.S. Food and Drug Administration has approved UCB's Kygevvi, marking a historic milestone for patients with thymidine kinase 2 deficiency (TK2d), an ultra-rare inherited mitochondrial disorder that has lacked…

Continue Reading Breakthrough FDA Approval Offers First-Ever Treatment for Life-Threatening Mitochondrial Energy Disorder

Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 1

As noted in a recent article published in Inside Precision Medicine, in 1992 gene therapy was often discussed but seldom practiced.  When Jim Wilson MD, PhD attended Penn State, gene…

Continue Reading Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 1

Unlocking a New Era: Illumina’s 5-Base Solution Bridges Genomics and Epigenomics for Multiomic Discovery

Illumina, Inc. has unveiled its groundbreaking 5-base solution, setting a new standard for multiomic research by enabling scientists to simultaneously analyze genomic and epigenomic information from a single sample. According…

Continue Reading Unlocking a New Era: Illumina’s 5-Base Solution Bridges Genomics and Epigenomics for Multiomic Discovery

Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Merck has announced a significant expansion of its clinical development program for tulisokibart (MK-7240), an investigational monoclonal antibody targeting the inflammatory mediator TL1A. Reported by Drugs.com, in October 2025, the…

Continue Reading Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Genetic Risk for Dilated Cardiomyopathy May Elevate Vulnerability to Secondary Cardiomyopathies

Emerging research highlights the role of genetic predisposition in the development of secondary cardiomyopathies triggered by environmental stressors such as pregnancy, alcohol use, and cancer therapy. Findings published in JAMA…

Continue Reading Genetic Risk for Dilated Cardiomyopathy May Elevate Vulnerability to Secondary Cardiomyopathies